364794-57-0 Usage
General Description
1-(5-Bromo-2-pyridinyl)-4-ethylpiperazine is a chemical compound that consists of a piperazine ring with an ethyl and bromo-pyridinyl group attached. It is commonly used in medicinal chemistry as a building block for drug discovery and development. The presence of the bromo and pyridinyl groups in the molecule makes it a valuable intermediate for the synthesis of various pharmaceuticals, especially those targeting the central nervous system. 1-(5-Bromo-2-pyridinyl)-4-ethylpiperazine has shown potential in the treatment of neurological disorders and has been studied for its role as a potential therapeutic agent in conditions such as schizophrenia, anxiety, and depression. Additionally, it is also employed in research involving the synthesis of novel compounds for medicinal purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 364794-57-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,4,7,9 and 4 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 364794-57:
(8*3)+(7*6)+(6*4)+(5*7)+(4*9)+(3*4)+(2*5)+(1*7)=190
190 % 10 = 0
So 364794-57-0 is a valid CAS Registry Number.
InChI:InChI=1/C11H16BrN3/c1-2-14-5-7-15(8-6-14)11-4-3-10(12)9-13-11/h3-4,9H,2,5-8H2,1H3
364794-57-0Relevant articles and documents
NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS
-
Paragraph 0265; 0266; 0267, (2020/04/09)
The present invention is related to new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
New phenylpyridylpiperazine compounds
-
Page/Page column 4, (2008/06/13)
A compound selected from those of formula (I): [image] wherein: X represents a C(O) or SO2 group, R1 represents an aryl group or a group NR3R4 wherein R3 and R4 are as defined in the description, R2 represents an alkyl, (C3-C8)cycloalkyl or (C3-C8)cycloalkyl-(C1-C6)alkyl group, its isomers, and addition salts thereof, and medicinal products containing the same which are useful in treating conditions treatable by antagonists of type H3 central histamine receptors.
